Background
Malaria is still one of the most serious infections in the world, with more than 300 million clinical cases and 1 million deaths per year. Currently, the artemisinin-based combination therapy (ACT) has been considered to be the most effective option and introduced in many areas of the world. However, there are many regions where those drugs are not available because of the higher expense of artemisinin. Moreover, WHO recently reported the emergence of artemisinin-resistant parasites. Development of novel anti-malarial drugs with fewer side effects, low cost, and preferably different mechanisms, have been urged as soon as possible.

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: